AAN 2026: How Identifying Genetic DEEs Within Existing Trial Data Could Expand the Role of Cannabidiol in Epilepsy Treatment

Summary: Doctors recently looked back at clinical trials for a severe type of epilepsy called Lennox-Gastaut syndrome (LGS). They realized that LGS isn't just one single disease. Instead, many patients actually have underlying genetic conditions known as DEEs.

By digging into the old data, researchers found 53 patients with these specific genetic DEEs. The great news? The medication cannabidiol (CBD) worked just as well for them, with the exact same safety profile. This means CBD could safely help treat a much wider range of genetic epilepsies than doctors previously thought!

Source: Pharmacy Times URL: pharmacytimes.com/view/aan-2026-how-identifying-genetic-dees-within-existing-trial-data-could-expand-the-role-of-cannabidiol-in-epilepsy-treatment (opens in new tab)